Genomic Testing Cooperative (GTC) Company Profile

Background

Overview

Genomic Testing Cooperative (GTC), established in 2018, is a molecular diagnostics company specializing in comprehensive genomic profiling for both solid tumors and hematologic malignancies. Operating on a cooperative business model, GTC collaborates with laboratories, hospitals, and medical professionals to share resources, thereby enhancing cost efficiency, turnaround times, and diagnostic quality.

Mission and Vision

GTC's mission is to provide advanced genomic profiling for cancers to communities globally at an affordable price. The company aims to democratize access to precision medicine by enabling local physicians to utilize cutting-edge diagnostic information. GTC envisions driving oncology forward by allowing more patients to contribute their unique cancer experiences to the expanding body of cancer genomics data, thereby fulfilling the promise of individualized care.

Key Strategic Focus

Core Objectives

• Comprehensive Genomic Profiling: GTC focuses on detailed analysis of DNA and RNA in hematologic neoplasms and solid tumors, utilizing next-generation sequencing (NGS) technology to provide insights into tumor signatures.

• Cooperative Model: By partnering with various medical entities, GTC shares resources to improve cost efficiency, turnaround times, and diagnostic quality.

Specialization Areas

• Hematologic Malignancies: Offering comprehensive molecular profiling to detect and differentiate driver and sub-clonal mutations, determine prognosis, and identify targeted therapies.

• Solid Tumors: Providing NGS testing covering clinically relevant genes, including tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD), fusions/translocations, copy number variations, amplifications, and deletions.

• Liquid Biopsy: Conducting non-invasive genomic testing on cell-free DNA (cfDNA) and cell-free RNA (cfRNA) to identify molecular abnormalities, reducing the need for tissue or bone marrow samples.

Key Technologies

• Next-Generation Sequencing (NGS): Utilized for comprehensive DNA and RNA profiling.

• Artificial Intelligence (AI): Informatics tools employing AI and sophisticated algorithms to interpret complex data sets, enhancing diagnostic precision.

Primary Markets

GTC targets the oncology diagnostics market, serving laboratories, hospitals, oncology practices, and medical professionals seeking advanced genomic profiling solutions.

Financials and Funding

Funding History

Specific details regarding GTC's funding history, total funds raised, and notable investors are not publicly disclosed.

Utilization of Capital

GTC invests in technological advancements, including AI-driven informatics tools and NGS technology, to enhance diagnostic capabilities and expand its cooperative network.

Pipeline Development

Key Offerings

• Hematology Profile Plus: Provides molecular data for selecting targeted therapy and accurate diagnosis of various myeloid and lymphoid neoplasms, including gene fusions, chromosomal gains and losses, and molecular immunoprofiling.

• Solid Tumor Profile Plus: Offers information on targetable mutations, fusion genes, tumor cell origin, and the presence or absence of HRD.

• Liquid Biopsy Profiles: Designed for tumor-informed monitoring and reducing the need for invasive biopsies.

Development Stages

GTC's tests have received various accreditations, including Medicare approval, New York State approval, and CE Mark, indicating validation and readiness for clinical use.

Target Conditions

GTC's profiling tests target a wide range of cancers, including but not limited to leukemia, lymphoma, breast cancer, lung cancer, and colorectal cancer.

Anticipated Milestones

GTC continues to expand its cooperative network and enhance its testing capabilities, with ongoing collaborations and technological innovations aimed at improving patient care.

Technological Platform and Innovation

Proprietary Technologies

• Interprestation Software Suite: A web-based platform providing partner labs with access to analyzed sequencing data and reporting tools.

Scientific Methodologies

• Targeted Transcriptome Analysis: Utilizing AI algorithms to distinguish between 45 different diagnostic classes, providing probability scores for accurate diagnosis.

AI-Driven Capabilities

• RNAnalysis Algorithm: Distinguishes between various diagnostic classes with high accuracy.

• TraceWork Algorithm: Further refines diagnoses by differentiating between entities with similar high probability scores.

Leadership Team

Key Executives

• Dr. Maher Albitar: Founder, Chief Executive Officer, and Chief Medical Officer. Dr. Albitar has held senior roles at numerous diagnostic laboratories and was a tenured professor at MD Anderson Cancer Center. He has over 300 publications and authored over 50 patents.

Key Contributions

Dr. Albitar has committed his life to advancing cancer diagnostics and democratizing testing, leading GTC's mission to revolutionize diagnostics and scientific discovery.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within GTC's leadership team.

Competitor Profile

Market Insights and Dynamics

The genomic testing market is experiencing significant growth, driven by advancements in precision medicine and increasing demand for personalized cancer diagnostics.

Competitor Analysis

• Invitae Corporation: Offers a wide range of genetic testing services but faced financial challenges, filing for Chapter 11 bankruptcy in early 2024.

• Myriad Genetics, Inc.: Provides genetic testing and precision medicine solutions, including prognostic and diagnostic tools.